Update on chemoradiotherapy for head and neck cancer

Athanassios Argiris

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Locoregionally advanced head and neck cancer is associated with a poor prognosis despite treatment with surgery or radiation or both. In the past several years, chemotherapy has become an integral part of potentially curative therapy for head and neck cancer and has been increasingly used to achieve the goals of organ preservation and prolongation of survival. Since 1998, many randomized studies that compared concurrent chemoradiotherapy with radiotherapy alone have been published. These studies used different chemotherapy regimens, either single-agent or combination, and various radiation fractionation schemes and almost uniformly supported the superiority of chemoradiotherapy over radiotherapy alone in terms of locoregional control as well as overall survival. Given the toxicity of concurrent chemoradiotherapy, careful selection of patients is critical. Many issues remain to be addressed in future trials, including the optimal chemotherapy regimen, the use of altered fractionation radiotherapy, and the role of induction chemotherapy.

Original languageEnglish (US)
Pages (from-to)323-329
Number of pages7
JournalCurrent Opinion in Oncology
Volume14
Issue number3
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Chemoradiotherapy
Head and Neck Neoplasms
Radiotherapy
Drug Therapy
Radiation
Organ Preservation
Induction Chemotherapy
Patient Selection
Therapeutics

ASJC Scopus subject areas

  • Cancer Research

Cite this

Update on chemoradiotherapy for head and neck cancer. / Argiris, Athanassios.

In: Current Opinion in Oncology, Vol. 14, No. 3, 2002, p. 323-329.

Research output: Contribution to journalArticle

Argiris, Athanassios. / Update on chemoradiotherapy for head and neck cancer. In: Current Opinion in Oncology. 2002 ; Vol. 14, No. 3. pp. 323-329.
@article{65c6f617536a492a92e61a91b421f1a1,
title = "Update on chemoradiotherapy for head and neck cancer",
abstract = "Locoregionally advanced head and neck cancer is associated with a poor prognosis despite treatment with surgery or radiation or both. In the past several years, chemotherapy has become an integral part of potentially curative therapy for head and neck cancer and has been increasingly used to achieve the goals of organ preservation and prolongation of survival. Since 1998, many randomized studies that compared concurrent chemoradiotherapy with radiotherapy alone have been published. These studies used different chemotherapy regimens, either single-agent or combination, and various radiation fractionation schemes and almost uniformly supported the superiority of chemoradiotherapy over radiotherapy alone in terms of locoregional control as well as overall survival. Given the toxicity of concurrent chemoradiotherapy, careful selection of patients is critical. Many issues remain to be addressed in future trials, including the optimal chemotherapy regimen, the use of altered fractionation radiotherapy, and the role of induction chemotherapy.",
author = "Athanassios Argiris",
year = "2002",
doi = "10.1097/00001622-200205000-00012",
language = "English (US)",
volume = "14",
pages = "323--329",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Update on chemoradiotherapy for head and neck cancer

AU - Argiris, Athanassios

PY - 2002

Y1 - 2002

N2 - Locoregionally advanced head and neck cancer is associated with a poor prognosis despite treatment with surgery or radiation or both. In the past several years, chemotherapy has become an integral part of potentially curative therapy for head and neck cancer and has been increasingly used to achieve the goals of organ preservation and prolongation of survival. Since 1998, many randomized studies that compared concurrent chemoradiotherapy with radiotherapy alone have been published. These studies used different chemotherapy regimens, either single-agent or combination, and various radiation fractionation schemes and almost uniformly supported the superiority of chemoradiotherapy over radiotherapy alone in terms of locoregional control as well as overall survival. Given the toxicity of concurrent chemoradiotherapy, careful selection of patients is critical. Many issues remain to be addressed in future trials, including the optimal chemotherapy regimen, the use of altered fractionation radiotherapy, and the role of induction chemotherapy.

AB - Locoregionally advanced head and neck cancer is associated with a poor prognosis despite treatment with surgery or radiation or both. In the past several years, chemotherapy has become an integral part of potentially curative therapy for head and neck cancer and has been increasingly used to achieve the goals of organ preservation and prolongation of survival. Since 1998, many randomized studies that compared concurrent chemoradiotherapy with radiotherapy alone have been published. These studies used different chemotherapy regimens, either single-agent or combination, and various radiation fractionation schemes and almost uniformly supported the superiority of chemoradiotherapy over radiotherapy alone in terms of locoregional control as well as overall survival. Given the toxicity of concurrent chemoradiotherapy, careful selection of patients is critical. Many issues remain to be addressed in future trials, including the optimal chemotherapy regimen, the use of altered fractionation radiotherapy, and the role of induction chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0036256065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036256065&partnerID=8YFLogxK

U2 - 10.1097/00001622-200205000-00012

DO - 10.1097/00001622-200205000-00012

M3 - Article

C2 - 11981279

AN - SCOPUS:0036256065

VL - 14

SP - 323

EP - 329

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 3

ER -